INCY vs VNDA: fair value comparison
Incyte Corporation and Vanda Pharmaceuticals Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| INCY | VNDA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $124.37 | $5.23 |
| 12-month range | $85.98–$119.52 | $4.47–$8.25 |
| Sector rank | #35 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | A | D |
| Momentum grade | A | — |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: INCY fair value analysis · VNDA fair value analysis